Clinical Trials Logo

Metastatic Lung Cancer clinical trials

View clinical trials related to Metastatic Lung Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03514329 Not yet recruiting - Lung Cancer Clinical Trials

Vapor Ablation for Localized Cancer Lesions

VAPORIZED
Start date: September 1, 2024
Phase: N/A
Study type: Interventional

This study is a prospective, single-arm, multi-center, pilot trial of Bronchoscopic Thermal Vapor Ablation for Lung Cancer (BTVA-C) in patients with primary lung cancer or metastatic cancer in the lung. Patients who have consented to participate in this study (enrolled) will be subject to eligibility screening and baseline assessments, prior to undergoing the BTVA-C procedure. Only patients that meet all of the inclusion criteria and none of the exclusion criteria will receive vapor ablation treatment. Patients will be followed for up to 12 months.

NCT ID: NCT01814150 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel

Start date: April 2013
Phase: N/A
Study type: Observational

Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer. One of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein. Retrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated with the outcome of docetaxel based therapy in cancer patients. The investigators aim to prospectively study the association between the plasma level of alpha 1 acid glycoprotein and the outcome of docetaxel based therapy in cancer patients.